ImmunityBio Faces Legal Trouble Over Misleading Efficacy Claims During Recent Class Action Lawsuit

ImmunityBio's Securities Class Action Overview

ImmunityBio, Inc. (NASDAQ: IBRX) is currently embroiled in a securities class action lawsuit that could have significant implications for the company and its shareholders. This legal action seeks to represent those who bought or acquired ImmunityBio securities between January 19, 2026, and March 24, 2026. The lawsuit has arisen due to allegations that the company misled investors regarding the efficacy of its lead biologic product, Anktiva.

Background of the Case

The controversy began with a podcast featuring ImmunityBio’s executive chairman and Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong, aired on January 19, 2026. In this podcast, he made several assertions about Anktiva, an FDA-approved immunotherapy aimed primarily at treating non-muscle invasive bladder cancer (NMIBC). Dr. Soon-Shiong controversially claimed that Anktiva could potentially treat all types of cancer, a declaration that raised eyebrows within the scientific and medical communities.

Shortly after the podcast was released, on March 24, 2026, the FDA issued a warning letter to ImmunityBio indicating that the promotional materials associated with Anktiva were misleading. Specifically, the FDA highlighted that these materials falsely suggested that Anktiva could cure and prevent all forms of cancer, which was not substantiated by clinical data. Following this news, ImmunityBio’s stock plummeted over 21%, wiping out nearly $2 billion of the company’s market capitalization.

Implications of the Warning Letter

The FDA's warning was a stark indication of the potential regulatory repercussions facing ImmunityBio. In its letter, the FDA pointed out that the company's advertising fails to provide essential information regarding the full scope of Anktiva's FDA-approved uses. This oversight, experts have argued, not only jeopardizes investor confidence but also poses a significant public health risk by creating unrealistic expectations regarding the drug's efficacy.

With claims that Anktiva could lead to long-term cancer-free status for all NMIBC patients, the FDA's response was particularly severe, stating that these promotions grossly misrepresented the benefits of the drug. Due to such far-reaching allegations, Hagens Berman, a national shareholders rights law firm, has initiated investigations into potential violations of federal securities laws by ImmunityBio.

Call to Action for Investors

In light of these developments, Hagens Berman is reaching out to those who invested in ImmunityBio and experienced significant financial losses, urging them to submit their claims. The law firm is also interested in hearing from any individuals who have insider knowledge that could assist in their ongoing investigation. For those concerned about their investment, this situation underscores the importance of compliance and transparency in healthcare messaging, particularly as it pertains to life-saving treatments.

The Bigger Picture

This lawsuit not only reflects individual grievances but highlights broader issues within the biotechnology industry, particularly the responsibilities of companies when marketing their products. Given the complexities of drug approval and marketing, the stakes are high, both for patient safety and shareholder value. As the case moves forward, ImmunityBio's future and the integrity of its claims regarding Anktiva will remain in the spotlight.

Investors are encouraged to stay informed on the outcomes of this legal battle and consider the implications for similar investing behaviors within the biotech sector.